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Abstract 
Background & Aims  
Chronic liver disease presents a major global public health challenge. Stratification of 
asymptomatic, at-risk patients in primary care using non-invasive methods has the 
potential to address this by identifying those likely to progress. We therefore 
evaluated variant alleles at loci associated with non-alcoholic fatty liver disease 
(NAFLD) as genetic determinants of substantial liver injury in patients with disease 
risk factors.  
Methods 
Levels of serum procollagen III (PIIINP), an established fibrosis and steatohepatitis 
marker, were determined in 467 people who had type 2 diabetes and/or BMI>27.3 
(identified from registration with general practitioners) in this observational cross-
sectional study. Patients were genotyped for characterised risk alleles in PNPLA3 
(rs738409), GCKR (rs1260326) and TM6SF2 (rs58542926) and associations with 
PIIINP assessed.  
Results 
The risk alleles in PNPLA3, GCKR or TM6SF2 were not found to be individually 
associated with the presence of a disease risk factor and were not significantly more 
common in patients with raised serum PIIINP. The prevalence of possession of both 
PNPLA3 and GCKR variant alleles combined was significantly higher in at-risk 
patients with clinically significant liver disease indicated by serum PIIINP above 11 
ng/ml (P=0.014).  
Conclusions 
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Genotyping therefore has limited value for predicting severe liver disease in at-risk 
individuals identified in a community setting.  
 
Abstract word count: 205 
 
 
 
Key words: PNPLA3, GCKR, TM6SF2, NAFLD 
 
Key points: 
• We evaluated the potential clinical utility of genotyping at 3 loci in the 
stratification of asymptomatic individuals for chronic liver disease in the 
community.  
• Risk alleles in PNPLA3, GCKR or TM6SF2 were not individually associated 
with risk factors for non-alcoholic fatty liver disease, type 2 diabetes, 
BMI>27.3) or significantly higher levels of the fibrosis biomarker, PIIINP.  
• Cross-sectional analysis showed at-risk individuals with high levels of PIIINP 
were more likely to be carriers of both PNPLA3 and GCKR risk alleles in 
combination.  
• We conclude that combined PNPLA3 and GCKR alleles may be considered 
for incorporating genetic risk into diagnostic or prognostic algorithms. 
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Introduction 
Chronic liver disease presents a major global public health challenge: liver-related 
deaths are rising in the UK (1) with liver cirrhosis being the third most common cause 
of premature death in people aged below 55 years (2). Given that many culprits in 
the aetiopathogenesis of chronic liver disease (alcohol, obesity and insulin 
resistance) are potentially preventable, there exists an unmet need to risk-stratify 
individuals prior to the onset of established cirrhosis, in order to introduce effective 
intervention. Risk stratification is problematic in early stages of liver disease as the 
majority of affected patients are asymptomatic. The absence of a validated non-
invasive biomarker to reliably diagnose or exclude liver disease has given rise to the 
use of a variety of strategies in order to optimise its detection (3); reviewed by (4). 
 
Non-invasive methods for quantifying liver fibrosis, such as the enhanced liver 
fibrosis (ELF) serum biomarker panel, represent a major advance in availability of 
strategies with which to assess patients at risk of liver disease in the community (5, 
6). In particular, measurement of amino-terminal peptide of procollagen III (PIIINP), a 
component of this panel, has been established for determining hepatic fibrosis in 
methotrexate therapy (7) and was identified as an accurate biomarker in 
discriminating between early-stage disease and more severe steatohepatitis (8).  
 
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of disease severity 
ranging from simple steatosis (‘fatty liver’) through steatohepatitis to cirrhosis. 
Genetic variants, which predispose to NAFLD have been identified from genome-
wide association studies (reviewed by (9, 10). Three separate single nucleotide 
polymorphism functional variants, shown to confer increased susceptibility to hepatic 
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triglyceride accumulations and fibrogenesis, have been robustly validated in large 
independent cohorts and supporting evidence provided by mechanistic studies. The 
rs738409 (C>G) variant in adiponutrin (PNPLA3), has consistently been 
demonstrated to correlate with increased severity of NAFLD (10-15). An association 
has also been established between the rs1260326 (C>T) variant within the 
glucokinase regulator (GCKR) and steatosis and fibrosis in NAFLD (16, 17). More 
recently, variant rs58542926 (C>T) in transmembrane 6 superfamily 2 (TM6SF2) 
was found to be associated with NAFLD (18-20). 
  
In this observational, cross-sectional study, we determined the genotype at these 3 
loci in 467 asymptomatic adults with risk factors for NAFLD, identified in primary 
care. The observed allele frequencies in patients were compared to literature values 
and to the frequencies in a geographically similar cohort of biopsy-proven NAFLD 
patients. We then assessed the influence of common genetic variants in PNPLA3 
(genotype GG), GCKR (genotype TT) and TM6SF2 (genotype CT or TT) on the 
degree of liver fibrosis as indicated by the serum biomarker PIIINP. Additionally, we 
analysed the effects of possession of two separate risk alleles in combination on the 
likelihood of clinically significant disease. 
 
Patients and methods 
Primary care cohort:  
Asymptomatic adult patients were recruited from a general medical practice in 
Leicester, UK, with a total patient population of 4600 (4150 adults). Patients were 
identified from electronic primary care patient records if they possessed at least one 
of the following risk factors for NAFLD (1) Type 2 diabetes mellitus; (2) BMI >27.3 
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recorded in the past 5 years, and were invited to attend a risk stratification pathway 
for chronic disease previously described (21-23). The BMI cut-off was selected a 
priori based on the high prevalence of patients registered at the practice with Asian 
ethnicity. This is in accordance with recommendations by the World Health 
Organisation due to the higher risk of type 2 diabetes and cardiovascular disease at 
a lower BMI in Asians compared to other European groups (23, 24). Patients with 
type 2 diabetes were identified from primary care records; if no coding was given, it 
was assumed that this factor was not present. The study protocol was approved by 
the National Research Ethics Service Committee East Midlands-Leicester (Ref: 
13/EM/0123); written informed consent was obtained from all participants.  
 
Non-invasive analyses for at-risk patients: 
 
Demographic data were recorded, and blood samples were taken for DNA 
extraction, clinical testing and biomarker analysis at the time of study visit. Serum 
was prepared from coagulated blood and stored at -80°C within 4 hours for ELF 
testing by iQur (London, UK). EDTA-anticoagulated whole blood stored at -80°C was 
used for DNA extraction.  
 
NAFLD cohort: 
 
DNA samples available from a cohort of biopsy-proven NAFLD patients were also 
included for cross-sectional analysis. These patients were recruited consecutively 
from hepatology clinics at the Nottingham University Hospitals NHS Trust between 
2002 and 2010. NAFLD was diagnosed on the basis of the following criteria: a liver 
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biopsy showing histology consistent with NAFLD; a weekly ethanol consumption of 
<14 units for women and <21 units for men; appropriate exclusion of other causes of 
liver disease including alcohol, drugs, autoimmune or viral hepatitis, or cholestatic or 
metabolic/genetic liver disease. These were collected as part of a separate study 
approved by the Nottingham Research Ethics Committee 2 (Ref: GM010201) 
described previously (25, 26); all participants gave informed written consent.  
 
Genotyping:  
 
Genomic DNA was isolated using Flexigene Kit (Qiagen, UK). Restriction fragment 
length polymorphism methodology was used to determine the genotype at PNPLA3 
rs738409, GCKR rs1260326 and TM6SF2 rs58542926 using primer pairs: 
TGGAGAAAGCTTATGAAGGATCAG/ CAGCTGTGGCTACTCTGTCTG, 
GGGTCTTAGGGTACCTGCTCAGAGG/ GGTAACCCATGACCTTGCCCAGC, and 
CCTGGGCTCAAGCGATCCTCATGC / 
CCAGGTATAATCCCAGCTACTCAGGAGG, respectively. The PCR amplified 
products were digested with FokI (PNPLA3), MspI (GCKR) and Hpy188I (TM6SF2), 
to identify wild type and variant alleles (New England Biolabs, UK).  
 
Statistics:  
 
Descriptive statistics were computed for all variables using arithmetic and geometric 
means (for non-normally distributed data) along with their respective standard 
deviations (SD) and 95% confidence intervals (CI) using SPSS (v. 22.0). The 
differences between subgroups were explored using chi-squared test for categorical 
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variables and t-test and Mann-Whitney test (for 2 groups) or Kruskall-Wallis test (for 
multiple groups) for continuous normally distributed and non-normally distributed 
data, respectively. Chi-square test was used to compare allele and genotype 
frequencies in patient sub-groups and to assess genotype distributions for Hardy-
Weinberg equilibrium. Correlation coefficients (Spearman’s rho) were used to 
determine the strength of the relationship of the variables. P values < 0.05 were 
considered statistically significant. 
 
Results 
 
Study population phenotype  
 
The primary practice comprised 4150 adults of which 51.8% were male. The 
patients’ ethnicity was poorly recorded within the electronic records but of the 
patients who attended the risk stratification pathway 69.9% were Caucasian and 
23.2% were of Asian ethnicity which is similar to the proportions seen with the local 
census data records. Within the practice population 298 patients were identified with 
type 2 diabetes and 1081 patients had a BMI >27.3. BMI values were available for 
87.7% of the patients. The type 2 diabetes prevalence of 7.2% in the practice is 
similar to the UK national prevalence of 6% (27). Obesity (BMI≥30) was less 
common in the cohort at 17.5% compared to 27% in the general UK population. Of 
the patients who attended the risk stratification pathway 467 with type 2 diabetes 
and/or BMI>27.3 provided a blood sample for genotyping DNA and determination of 
serum PIIINP. The characteristics of this cohort and the practice population are 
shown in Supplemental Table 1.  
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The baseline demographic and clinical data for the at-risk cohort is summarised in 
Table 1. In the genotyped cohort, a total of 61 patients (13%) had PIIINP levels 
above the 11 ng/ml threshold considered indicative of liver fibrosis grade ≥ F3 (8). 
Serum PIIINP levels correlated significantly with the presence of systemic 
hypertension, aspartate aminotransferase (AST) and BMI (data not shown). There 
were no significant differences in serum PIIINP levels between the Caucasian and 
Asian sub-populations (Supplemental Table 2). 
 
Genotypes and allele frequencies for PNPLA3, GCKR and TM6SF2 risk alleles 
 
The genotype for PNPLA3 (rs738409), GCKR (rs1260326) and TM6SF2 
(rs58542926) was determined in the at-risk primary care cohort and a biopsy-proven 
NAFLD patient cohort.  Table 2 shows the minor allele frequency (MAF) for each 
variant in each cohort, sub-groups and the European Population MAF from the 1000 
Genomes project (28). The genotype at the 3 loci, detailed in Supplemental Table 3, 
was in Hardy-Weinberg equilibrium for the tested cohorts (and in the sub groups 
analysed where >5 individuals with each genotype were included).  
 
Within the community at-risk cohort, the Caucasian sub-group had similar allele 
frequencies (Table 2) to other European populations (19, 28, 29). There were no 
significant differences in the PNPLA3, GCKR and TM6SF2 variant frequencies 
between the Caucasian and Asian sub-groups however, possession of the GCKR T 
allele was less common in Asians as in the reference populations. 
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Higher frequencies of PNPLA3, GCKR and TM6SF2 risk alleles in biopsy-proven 
NAFLD patients than in the at-risk patient cohort 
 
The individual PNPLA3, GCKR, TM6SF2 risk allele frequencies in the at-risk primary 
care cohort were compared to the frequencies in a cohort of 186 predominantly 
Caucasian, biopsy-proven NAFLD patients (age 58.0 (± 12.7), 61.5% male) also 
from central England (8, 26)  (Table 2). All 3 of these alleles were significantly more 
prevalent in the biopsy-proven disease cohort than the at-risk cohort: 32% of NAFLD 
patient chromosomes had the PNPLA3 variant, compared to 22% of primary care 
individuals with NAFLD risk factors (P=0.01). This corresponds to risk allele carriage 
in 53% of NAFLD hospital patients and in 39% of at-risk community patients 
(Supplemental Table 3). In diseased patients, 49% of chromosomes possessed the 
GCKR variant and 15% had the TM6SF2 variant compared to 36% and 10% of 
chromosomes in the NAFLD at-risk cohort, respectively (P<0.001 and P=0.04, 
respectively). This is consistent with previous reports of associations of these so-
called risk alleles with NAFLD progression to non-alcoholic steatohepatitis (NASH) 
(16, 18, 30). The observation that the at-risk cohort has lower risk allele frequencies 
than a diseased cohort, and has frequencies similar to that in the 1000 Genomes 
reference populations, demonstrates that the variants are not associated with 
possession of risk factors (being overweight or having diabetes), only with the 
development of liver disease.  
 
Association of combined PNPLA3 plus GCKR variant alleles with high PIIINP levels 
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We then assessed the prevalence of risk alleles in at-risk patients sub-divided using 
a cut-off of PIIINP levels above 11 ng/ml, considered to indicate significant fibrosis ≥ 
F3 and NASH diagnosis (8) as shown in Fig. 1. Individually, none of the risk alleles 
was significantly more prevalent in the 61 patients with elevated, clinically significant 
levels of PIIINP. As the PNPLA3 and GCKR variant alleles have been reported to 
interact to contribute to increased severity of NAFLD (17), we considered these two 
variants in combination (Fig. 1D). Analysis revealed a significantly higher proportion 
with the double variant PNPLA3 G* GCKR T* combination: 36% compared to 22% in 
those with PIIINP levels below this cut off (P=0.014). This double variant loci 
combination was significantly more prevalent in the patients with high serum PIIINP 
levels. In total, 110 (24%) at-risk patients had one or more risk alleles for both 
PNPLA3 and GCKR loci; 36 had PNPLA3 G* plus TM6SF2 T*. Since combinations 
including the TM6SF2 variant are less prevalent, numbers in our cohort were 
insufficient for analysis of this dual variant combination. 
 
In the NAFLD risk community cohort there were no significant associations between 
each separate risk allele (at the 3 loci), and PIIINP levels indicative of extracellular 
matrix remodelling associated with fibrosis. We found ALT levels were significantly 
higher (P<0.001) in NAFLD risk patients carrying one or more copies of the PNPLA3 
variant allele (29.6 (95% CI: 6-143) versus 24.8 (95% CI: 7-93) IU/l) as reported 
previously for an obese cohort (31). If only our 240 obese, NAFLD-risk patients were 
considered, we similarly found a significant association between possession of the 
PNPLA3 variant and serum PIIINP levels (P=0.040; 8.43 ng/ml (95% CI: 3-25) in 
carriers versus 7.61 ng/ml  (95% CI: 2-24) in non-carriers). Levels of PIIINP were 
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also higher in PNPLA3 variant carriers with either BMI>27.3 (n=406) or diabetes 
(n=120), but this did not reach significance for either group.  
 
Discussion 
Heritable components interact with environmental influences, such as diet and 
alcohol intake, generating the observed individual disease susceptibility and inter-
individual variability of complex traits (32). In this study we have assessed the value 
of genotyping at 3 separate loci previously implicated in the development of chronic 
liver disease associated with common, lifestyle-related risk factors in a community 
setting. We have also been able to consider an interaction between two prevalent 
risk alleles in combination (PNPLA3 G and GCKR T), in contributing to serum PIINP 
levels, a surrogate biomarker for liver fibrosis.  
 
Non-invasive tools for estimation of fibrosis in patients are now widely available and 
applicable for population stratification in primary care (21). PIIINP released into 
circulation is thought to reflect collagen synthesis associated with extracellular matrix 
turnover at the site of disease, indicative of fibrosis. Serum PIIINP levels are widely 
utilised for monitoring liver fibrosis (7, 33). Transient elastography using Fibroscan© 
similarly correlates with histological fibrosis but may not be informative for fibrosis 
staging in as many patients compared to the ELF biomarker panel (5). PIIINP levels 
were previously established for diagnosis of liver injury characteristic of NASH and 
were associated with steatosis, lobular inflammation and ballooning histology (8). In 
our study, a threshold of PIIINP 11 ng/ml was suggestive of significant liver injury or 
severe levels of fibrosis in 61 patients within the at-risk cohort of 467 tested.  
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We confirm that the PNPLA3 variant is significantly more prevalent in diagnosed, 
secondary care NAFLD patients, as previously reported in several populations and 
established as a risk factor for disease in meta-analyses (12, 14, 15, 30, 34, 35). 
Here we additionally report increased prevalence of GCKR and TM6SF2 variants in 
biopsy-proven NAFLD patients (Table 2). These findings are consistent with cohorts 
of patients identified in secondary care practice being more likely to have more 
advanced disease when compared to those in the primary care setting.  In addition, 
in secondary care, patients are selected to liver biopsy based on the algorithms that 
identify those with more advanced liver disease.    
 
Numerous studies have suggested PNPLA3 genotyping is of value in the risk 
stratification of NAFLD patients (reviewed by (20, 36). The PNPLA3 variant was 
shown to confer increased risk of NAFLD in ‘healthy’ Korean males (37). However, 
one study found PNPLA3 genotyping to be of little value in detecting the presence of 
NAFLD (38) but it was suggested to have clinical utility in detecting NASH (39) and 
may assist in stratification for HCC surveillance (40). We did not find an association 
of this variant with non-invasive measures of fibrosis in patients at risk of NAFLD. 
However, when only obese patients were evaluated, the variant was associated with 
serum PIIINP indicative of more advanced fibrosis consistent with previous research 
(31, 41, 42). 
 
Similar to in general population studies (43), we found that serum triglyceride levels 
were elevated in at-risk individuals carrying the GCKR variant (but this did not reach 
statistical significance; data not shown), consistent with its effect increasing hepatic 
glucokinase activity (44) in at-risk individuals.  A synergistic effect of PNPLA3 and 
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GCKR variants was also previously reported associated with susceptibility to NAFLD 
in an Indian cohort and the multiplicative mechanistic effect suggested to arise via 
overlapping functionality in lipid processing pathways (17). Our observed increased 
prevalence of this variant combination in at-risk patients with predicted clinically 
significant fibrosis (Figure 1) is consistent with these genetic factors acting together 
to promote the development of disease.  
 
The main limitation of this study is that it cannot determine the key relationship 
between genetic background and liver disease progression over time as this would 
necessitate a longitudinal analysis rather than a cross-sectional study. Although our 
cohort is substantial, numbers are still restrictive for analysis of separate risk factors. 
The cohort includes people with diabetes or high BMI, or both and 61 people who 
also consume levels of alcohol above the National recommended limits (14 units per 
week) so there is heterogeneity in likely pathogenic processes which may distort our 
findings. There is also uncertain applicability to other cohorts with different ethnic 
make-up. Our cohort is reasonably representative of the UK population in terms of 
diabetes prevalence and alcohol consumption although obesity levels were lower 
than expected; it also included a substantial number of people with Asian ethnicity 
which have higher rates of NAFLD. However, the key strength is that the current 
study does overcome the selection bias of secondary care setting studies and uses 
the more relevant primary care patients which could be targeted for treatment.  
 
Ever since genetic factors were established as contributing to disease progression, 
genotyping has been proposed as a potential route to stratify patients for treatments. 
This report highlights the complexity of the disease mechanisms and likely 
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interaction between individual genes and lifestyle factors, making it difficult to 
establish a feasible screening process. Although possession of risk alleles is thought 
to predispose to disease severity, this research reveals that there is no simple 
relationship with degree of fibrosis in asymptomatic individuals with NAFLD risk 
factors. Further work including replication in other cohorts or incorporation into 
marker algorithms, may reveal that targeted genotyping of specific risk groups could 
be of value to identify asymptomatic patients likely to have significant levels of liver 
fibrosis or steatohepatitis for targeting interventions. 
 
  
Page 15 of 26 Liver International
16 
 
 
Acknowledgements: 
The views expressed are those of the authors and not necessarily those of the 
National Health Service, the National Institute for Health Research or the 
Department of Health. The study sponsors were not involved in this research or 
manuscript submission. We acknowledge Tim Card for his role in conceiving, 
designing and developing the community cohort study. We thank Melanie Lingaya 
and Yirga Falcone for excellent technical assistance and Digestive Diseases 
Research nurses for assisting with sample collection. 
  
Page 16 of 26Liver International
17 
 
 
 
 
References: 
 
1. BHALA N, AITHAL G, FERGUSON J. How to tackle rising rates of liver disease in 
the UK. BMJ 2013; 346: f807. 
2. MURRAY C J, LOPEZ A D. Measuring the global burden of disease. The New 
England journal of medicine 2013; 369(5): 448-57. 
3. ERGELEN R, AKYUZ U, AYDIN Y, EREN F, YILMAZ Y. Measurements of serum 
procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient 
elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver 
disease. European journal of gastroenterology & hepatology 2015; 27(6): 667-71. 
4. ARULANANDAN A, LOOMBA R. Non-invasive Testing for NASH and NASH with 
Advanced Fibrosis: Are We There Yet? Current hepatology reports 2015; 14(2): 109-18. 
5. FRIEDRICH-RUST M, ROSENBERG W, PARKES J, HERRMANN E, ZEUZEM S, 
SARRAZIN C. Comparison of ELF, FibroTest and FibroScan for the non-invasive 
assessment of liver fibrosis. BMC gastroenterology 2010; 10: 103. 
6. WAHL K, ROSENBERG W, VASKE B, et al. Biopsy-controlled liver fibrosis staging 
using the enhanced liver fibrosis (ELF) score compared to transient elastography. PloS one 
2012; 7(12): e51906. 
7. KHAN S, SUBEDI D, CHOWDHURY M M. Use of amino terminal type III procollagen 
peptide (P3NP) assay in methotrexate therapy for psoriasis. Postgraduate medical journal 
2006; 82(967): 353-4. 
8. TANWAR S, TREMBLING P M, GUHA I N, et al. Validation of terminal peptide of 
procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients 
with nonalcoholic fatty liver disease. Hepatology 2013; 57(1): 103-11. 
9. KAHALI B, HALLIGAN B, SPELIOTES E K. Insights from Genome-Wide Association 
Analyses of Nonalcoholic Fatty Liver Disease. Seminars in liver disease 2015; 35(4): 375-91. 
10. ANSTEE Q M, SETH D, DAY C P. Genetic Factors That Affect Risk of Alcoholic and 
Nonalcoholic Fatty Liver Disease. Gastroenterology 2016; 150(8): 1728-44 e7. 
11. ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers 
susceptibility to nonalcoholic fatty liver disease. Nature genetics 2008; 40(12): 1461-5. 
12. SOOKOIAN S, PIROLA C J. Meta-analysis of the influence of I148M variant of 
patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and 
histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53(6): 1883-94. 
13. TREPO E, ROMEO S, ZUCMAN-ROSSI J, NAHON P. PNPLA3 gene in liver 
diseases. Journal of hepatology 2016; 65(2): 399-412. 
14. VALENTI L, AL-SERRI A, DALY A K, et al. Homozygosity for the patatin-like 
phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with 
nonalcoholic fatty liver disease. Hepatology 2010; 51(4): 1209-17. 
15. SHEN J H, LI Y L, LI D, WANG N N, JING L, HUANG Y H. The rs738409 (I148M) 
variant of the PNPLA3 gene and cirrhosis: a meta-analysis. Journal of lipid research 2015; 
56(1): 167-75. 
16. PETTA S, MIELE L, BUGIANESI E, et al. Glucokinase regulatory protein gene 
polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PloS one 2014; 9(2): 
e87523. 
17. TAN H L, ZAIN S M, MOHAMED R, et al. Association of glucokinase regulatory gene 
polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study 
with adiponutrin gene. Journal of gastroenterology 2014; 49(6): 1056-64. 
18. LIU Y L, REEVES H L, BURT A D, et al. TM6SF2 rs58542926 influences hepatic 
fibrosis progression in patients with non-alcoholic fatty liver disease. Nature communications 
2014; 5: 4309. 
Page 17 of 26 Liver International
18 
 
19. KOZLITINA J, SMAGRIS E, STENDER S, et al. Exome-wide association study 
identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. 
Nature genetics 2014; 46(4): 352-6. 
20. DONGIOVANNI P, ROMEO S, VALENTI L. Genetic Factors in the Pathogenesis of 
Nonalcoholic Fatty Liver and Steatohepatitis. BioMed research international 2015; 2015: 
460190. 
21. HARMAN D J, RYDER S D, JAMES M W, et al. Direct targeting of risk factors 
significantly increases the detection of liver cirrhosis in primary care: a cross-sectional 
diagnostic study utilising transient elastography. BMJ open 2015; 5(4): e007516. 
22. TANAJEWSKI L, HARRIS R, HARMAN D, et al. Earlier Detection And Treatment of 
Non-Alcoholic Fatty Liver Disease: An Economic Evaluation to Appraise An Innovative 
Diagnostic Pathway to Detect And Intervene Where There Are Known Risk Factors. Value in 
health : the journal of the International Society for Pharmacoeconomics and Outcomes 
Research 2015; 18(7): A627. 
23. HARRIS R, DELAHOOKE T, CARD T, GUHA I, AITHAL G. OC-032 Type 2 Diabetes 
and Obesity will Drive the Burden of Liver Cirrhosis in the Next Two Decades. Gut 2016; 
65(Suppl 1): A19-A20. 
24. CONSULTATION W H O E. Appropriate body-mass index for Asian populations and 
its implications for policy and intervention strategies. Lancet 2004; 363(9403): 157-63. 
25. AITHAL G P, THOMAS J A, KAYE P V, et al. Randomized, placebo-controlled trial of 
pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 
2008; 135(4): 1176-84. 
26. GROVE J I, ANTOINE D J, KAYE P, et al. Do Serum Markers of Cell Injury and 
Death Have Potential to Become Mechanistic Markers in Non-Alcoholic Fatty Liver Disease 
(Nafld)? Gut 2014; 63: A245-A46. 
27. GATINEAU M. H C, HOLMAN N., OUTHWAITE H.,, OLDRIDGE L. C A A E L. Adult 
obesity and type 2 diabetes. Public Health England 2014(PHE publications gateway number: 
2014211). 
28. GENOMES PROJECT C, AUTON A, BROOKS L D, et al. A global reference for 
human genetic variation. Nature 2015; 526(7571): 68-74. 
29. PALMER C N, MAGLIO C, PIRAZZI C, et al. Paradoxical lower serum triglyceride 
levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the 
PNPLA3 148M variant. PloS one 2012; 7(6): e39362. 
30. SPELIOTES E K, BUTLER J L, PALMER C D, et al. PNPLA3 variants specifically 
confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. 
Hepatology 2010; 52(3): 904-12. 
31. ROMEO S, SENTINELLI F, DASH S, et al. Morbid obesity exposes the association 
between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European 
descent. Int J Obes (Lond) 2010; 34(1): 190-4. 
32. LOOMBA R, SCHORK N, CHEN C H, et al. Heritability of Hepatic Fibrosis and 
Steatosis Based on a Prospective Twin Study. Gastroenterology 2015; 149(7): 1784-93. 
33. XIE Q, ZHOU X, HUANG P, WEI J, WANG W, ZHENG S. The performance of 
enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis. PloS one 
2014; 9(4): e92772. 
34. SOOKOIAN S, CASTANO G O, BURGUENO A L, GIANOTTI T F, ROSSELLI M S, 
PIROLA C J. A nonsynonymous gene variant in the adiponutrin gene is associated with 
nonalcoholic fatty liver disease severity. Journal of lipid research 2009; 50(10): 2111-6. 
35. ROTMAN Y, KOH C, ZMUDA J M, KLEINER D E, LIANG T J, NASH C R N. The 
association of genetic variability in patatin-like phospholipase domain-containing protein 3 
(PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 
52(3): 894-903. 
36. XU R, TAO A, ZHANG S, DENG Y, CHEN G. Association between patatin-like 
phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty 
liver disease: a HuGE review and meta-analysis. Scientific reports 2015; 5: 9284. 
Page 18 of 26Liver International
19 
 
37. PARK J H, CHO B, KWON H, et al. I148M variant in PNPLA3 reduces central 
adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver 
international : official journal of the International Association for the Study of the Liver 2015; 
35(12): 2537-46. 
38. KOTRONEN A, PELTONEN M, HAKKARAINEN A, et al. Prediction of non-alcoholic 
fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009; 
137(3): 865-72. 
39. HYYSALO J, MANNISTO V T, ZHOU Y, et al. A population-based study on the 
prevalence of NASH using scores validated against liver histology. Journal of hepatology 
2014; 60(4): 839-46. 
40. LIU Y L, PATMAN G L, LEATHART J B, et al. Carriage of the PNPLA3 rs738409 C 
>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated 
hepatocellular carcinoma. Journal of hepatology 2014; 61(1): 75-81. 
41. PETAJA E M, YKI-JARVINEN H. Definitions of Normal Liver Fat and the Association 
of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review. International 
journal of molecular sciences 2016; 17(5). 
42. STENDER S, KOZLITINA J, NORDESTGAARD B G, TYBJAERG-HANSEN A, 
HOBBS H H, COHEN J C. Adiposity amplifies the genetic risk of fatty liver disease conferred 
by multiple loci. Nature genetics 2017; 49(6): 842-47. 
43. SPARSO T, ANDERSEN G, NIELSEN T, et al. The GCKR rs780094 polymorphism 
is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related 
insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 2008; 51(1): 70-5. 
44. REES M G, WINCOVITCH S, SCHULTZ J, et al. Cellular characterisation of the 
GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 2012; 55(1): 114-22. 
 
 
  
Page 19 of 26 Liver International
20 
 
Table 1. Demographic and clinical characteristics of genotyped community patients 
with NAFLD risk factors. 
Variablesa  
Genotyped at-risk community cohort       
(n=467) 
Age: mean (SD) 57.1 (± 14.1) 
Males (%) 52.7 % 
Caucasians (%) 71.0% 
ALT  (IU/L) 26.57 (6.24-113.0) n=454 
Triglycerides (mmol/L) 
 
1.49 (0.28-7.8) n=453 
LDL cholesterol (mmol/L) 
 
2.78  (± 1.0) n=415 
HDL cholesterol (mmol/L) 
 
1.32 (0.53-3.28) n=455 
BMI (kg/m2) 30.81 (19.5-48.8) 
BMI >27.3 (%) 87.6 % 
Obese (%) 51.8 % 
Type 2 diabetes (%) 26.1 % 
PIIINP (ng/ml) 
 
7.57 (2.55-22.52) 
 
PIIINP >11 ng/ml  
(likely fibrosis grade ≥3) 13.1 %  
a Variables are expressed as geometric mean ± 95% CI, mean ± SD, or frequency 
(%) and number of cases. ALT= alanine transaminase. AST= aspartate 
transaminase. LDL= low-density lipoprotein. HDL= high-density lipoprotein. PIIINP= 
pro-collagen III. 
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Table 2 Comparison of individual minor allele frequencies (MAF) in patient groups 
and populations.  
Cohort PNPLA3 
rs738409 
MAF 
GCKR 
rs1260326 
MAF 
TM6SF2 
rs58542926 
MAF 
At-risk community cohort 
(n=467) 
0.22 0.36 0.10 
Biopsy-proven NAFLD 
hospital cohort  
(n=186) 
0.32 0.49 0.15 
Caucasian community 
patients (n=331) 0.22 0.38 0.10 
Asian community 
patients (n=108) 0.22 0.32 0.10 
1000 genomes European 
cohort a 0.23 0.41 0.07 
1000 genomes South 
Asian cohorta  0.25 0.20 0.11 
a
 (28) http://www.1000genomes.org/category/population 
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Figure Legend: 
 
Fig. 1 Distribution of risk allele genotypes in at-risk community patients with clinically 
significant serum PIIINP levels compared to those with levels of PIIINP below 
11ng/ml. (A) PNPLA3. (B) GCKR. (C) TM6SF2. (D) Combined PNPLA3 and GCKR 
variants. 
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